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ABSTRACT 
Osteoarthritis (OA), characterized by degeneration of the cartilaginous tissue in articular joints, 
severely impairs mobility in many people worldwide. The degeneration is thought to be mediated 
by inflammatory processes occurring in the tissue of the joint, including the cartilage. Intra-
articular administered Triamcinolone acetonide (TAA) is one of the drug treatments employed to 
ameliorate the inflammation and pain that characterizes OA. However, the penetration and 
distribution of TAA into the avascular cartilage is not well understood. We employed matrix-
assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI), which has been 
previously used to directly monitor the distribution of drugs in biological tissues, to evaluate the 
distribution of TAA in human cartilage after in vitro incubation. Unfortunately, TAA is not easily 
ionized by regular electrospray ionization (ESI) or MALDI. To overcome this problem, we 
developed an on-tissue derivatization method with Girard’s reagent T (GirT) in human incubated 
cartilage being able to study its distribution and quantify the drug abundance (up to 3.3 ng/µl). 
Our results demonstrate the depth of penetration of a corticosteroid drug in human OA cartilage 
using MALDI-MSI. 
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INTRODUCTION 
Osteoarthritis (OA) also known as degenerative arthritis or degenerative joint disease, results 
from the degeneration of cartilaginous tissue in joints and severely affects mobility. OA affects 
more than half of the population above 60 years of age making it the world’s most common age-
related disease.1,2 The use of small molecule drugs for treatment of cartilage pathology over the 
past decennia has been accompanied by a lack of understanding where in the joint they distribute. 
Especially potent drugs with pleiotropic effects such as corticosteroids can have several side 
effects associated. Local accumulation is potentially pathological depending on the joint tissue. 
Conversely, certain levels may be needed in tissues to achieve the desired effect. Understanding 
the local distribution of drugs, will help fine tuning the application of intra-articular drug 
therapies, either by adjusting concentrations, using different physicochemical versions of the drug 
or administration modes, such as controlled or targeted delivery. Triamcinolone acetonide (TAA) 
is a synthetic corticosteroid most commonly used as a local anti-inflammatory to treat the pain 
and inflammation associated with OA.3,4 5 Although the effects of corticosteroids on symptoms of 
OA are ascribed to the inhibition of inflammatory mediator production, this has not been 
unequivocally proven.1 In fact, data on the effects of corticosteroids on cartilage have been 
contradictory until now and may be context- and/or dose-dependent.3,6,7  
Different imaging modalities have been used to study OA; these include radiography8,9, 
ultrasonography10, computed tomography (CT)11,12, magnetic resonance imaging (MRI)13 and 
positron emission tomography (PET).14 While these methods are effective for diagnosing or 
following patient progress, these techniques do not provide biomolecular understanding of the 
disease pathology. Mass spectrometry imaging (MSI) is a relatively new biomolecular tool to 
study OA. Compared to conventional imaging techniques, such as MRI, PET or autoradiography, 
MSI offers several important advantages. First, it does not require the labeling of molecules and 
can produce high spatial resolution images. Moreover, MSI allows for the simultaneous detection 
of thousands of different molecules that can be detected from histological tissues sections in a 
single experiment. The first publication related to OA using MSI showed that it is possible to 
distinguish between healthy and OA cartilage at the molecular level using secondary ion mass 
spectrometry (SIMS).15 It has also been shown that matrix-assisted laser desorption/ionization 
mass spectrometry imaging (MALDI-MSI) is able to reveal OA-specific proteins16 and identify 
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peptides as markers of ageing and OA.17 The different markers in normal and OA synovium have 
shown the potential of this technique in furthering our understanding of the pathology. MSI is 
commonly applied in different drug discovery and development phases to study the efficiency, 
toxicity and pharmacokinetic properties of candidate molecules.18,19 MSI has been used for the 
detection of drugs in different organs such as kidney20,21, liver22, lung23,24, brain25 and even in 
hair26 , however, this method has never been applied to study drug distributions in cartilage.  
Unfortunately, TAA is difficult to detect by mass spectrometry due to the fact that the molecule is 
not easily protonated/deprotonated. Furthermore, it is susceptible to ion suppression by more 
abundant molecules such as lipids.27 In cases where compounds have poor ionization efficiency, a 
derivatization procedure to add a charged group directly to the molecule can increase ion yields. 
An additional benefit of derivatization with “soft” ionization mass spectrometry techniques such 
as MALDI is that the derivatization prevents isobaric overlay between the matrix and the 
molecules peaks by providing a shift of mass to higher m/z values where there are fewer matrix 
interferences. The most common derivatization reactions of carbonyl compounds reported for 
analysis by “soft” ionization mass spectrometry methods are based on the formation of oximes 
and hydrazones.28,29 Several requirements must be considered when choosing the ideal 
derivatization reagent. First, the reagent should be pre-charged or include a group having high 
proton affinity. Second, it must contain a suitable reactive group. Finally, it should be 
commercially available or synthesized using inexpensive reagents groups.28,30  
Here, we developed an on-tissue derivatization method using Girard’s reagent T (GirT), which is 
a quaternary ammonium acetylhydrazine chloride that forms water-soluble hydrazones with 
carbonyl compounds. GirT has been previously used for the derivatization and analysis of 
corticosteroids by MALDI-MSI.31 In a recent study, this reagent has been used to visualize 
testosterone in mouse testis32,33 and corticosterone in rat adrenal and mouse brain sections.27 We 
report that on-tissue GirT derivatization on human cartilage tissue sections enabled the detection 
of TAA. Accurate quantification of TAA was achieved using a deuterated TAA analogue (TAA-
d6). Furthermore, we were able to determine the distribution of TAA in human cartilage by 
normalizing the data against the labeled analogue. Our findings provide an optimized MALDI-
MSI approach to detect and quantify a corticosteroid drug (TAA) in human cartilage. 
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EXPERIMENTAL SECTION 
Chemicals and Reagents 
2,5-dihydroxybenzoic acid (DHB), triamcinolone acetonide (TAA), Girard’s reagent T (GirT), 
norhamane and trifluoroacetic acid (TFA) were purchased from Sigma Aldrich (Gillingham, 
Dorset, UK). Methanol (MeOH) and ethanol (EtOH) were purchased from Fisher Scientific 
(Loughborough, Leicestershire, UK). TAA-d6 was synthetized by Expert Synthesis Solutions 
(London, UK). Dulbecco’s modified Eagle’s medium (DMEM) and penicillin/streptomycin (P/S) 
were purchased from Thermo Fisher Scientific (Waltham, MA, USA). Fetal bovine serum was 
purchased from HyClone (Eindhoven, The Netherlands) and ammonium acetate was purchased 
from AMRESCO (Solon, OH, USA).  
Tissue Collection and Preparation 
Anonymous use of redundant tissue for research purposes is part of the standard treatment 
agreement with patients in the UMCU and is used in accordance with the code “appropriate use 
of redundant tissue for clinical research” guideline constructed by the Dutch Federation of 
Medical Research Societies (www.federa.org). The cartilage was obtained from three OA 
patients undergoing total knee arthroplasty and rinsed with PBS 1% penicillin/streptomycin 
(Figure 1a,b Supporting Information). Cartilage chips (between 5x5 and 10x10mm) were placed 
in a 24-well plate and incubated with DMEM supplemented with 10 % FBS and 1 % P/S. Based 
on previous cartilage explant studies45, TAA was added at two different concentrations (43.5 
ng/µl and 434.5 ng/µl) at a total volume of 500 µL for 48 hours in a humidified incubator in an 
environment of 5% CO2 and 37°C. As a control, the tissues were incubated with drug-free culture 
medium (Figure 1c Supporting Information). After the incubation, cartilage chips were rinsed 
with ice-cold ammonium acetate buffer (150 mM, pH 7.3), snap-frozen in liquid nitrogen, and 
stored at -80° C until analysis (Figure 1d Supporting Information).  
Snap-frozen tissues were sectioned at -20°C using a Leica cryostat (Leica Microsystems, 
Wetzlar) and deposited on indium tin oxide (ITO) glass slides (4-8 Ω resistance, Delta 
Technologies, USA).  
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Internal Standard  
The internal standard, triamcinolone acetonide-d6 (TAA-d6, 5 ng/µl) was sprayed on top of the 
tissue using the SunCollect sprayer (SunChrom, Friedrischsdorf, Germany) before application of 
the standard curve and the derivatization agent. Ten layers were applied at 40 μL/min (speed x: 
low 7, speed y: medium 1, Z position: 30). 
Standard Curve 
A dilution series of TAA was prepared in 70% MeOH at the following concentrations: 0.1, 0.5, 1, 
2, 10, 20, 30 and 50 ng/µl. A 10-µl aliquot of each concentration was mixed with 10 µl of GirT (5 
mg/mL in MeOH with 0.2% TFA). The dilution series was applied on a target plate in the 
following sequence: 0.5 µl of DHB (20 mg/mL in 70% MeOH with 0.2% TFA), 1.0 µl of the 
TAA solution and then 0.5 µl of DHB. For on-tissue experiments, 0.2 µl of each concentration 
was manually applied on blank cartilage tissue sections before the on-tissue chemical 
derivatization process. 
On-tissue Chemical Derivatization 
On-tissue derivatization of TAA was performed with the SunCollect automated pneumatic 
sprayer by applying GirT (5 mg/mL in MeOH with 0.2% TFA) in a series of 18 layers. The first 
layer was applied at 10 µL/min, the second layer was applied at 15 µL/min and all subsequent 
layers were sprayed at 20 µL/min (speed x: low 7, speed y: medium 1, Z position: 30). The 
coated tissue section was placed in a pipette tip box with 60 mL of 50% MeOH with 0.2% TFA, 
in an oven set at 40°C. After 150 min, the sample was removed and allowed to cool down and 
dry in a vacuum desiccator (room temperature, 15 min) before the matrix application in order to 
avoid subsequent hydrolysis.  
Matrix Application 
Fresh DHB solution (20 mg/mL in 70% MeOH with 0.2% TFA) was sprayed using the 
SunCollect automated pneumatic sprayer in a series of 30 layers. The first layer was applied at 10 
µL/min, the second layer was applied at 15 µL/min and all subsequent layers were sprayed at 20 
µL/min (speed x: low 7, speed y: medium 1, Z position: 40).  
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MS Acquisition 
A Waters MALDI HDMS SYNAPT G2-Si mass spectrometer (Waters Corporation, Manchester, 
UK) equipped with a 200-Hz, 355-nm neodymium-doped yttrium aluminum garnet (Nd:YAG) 
laser configured to acquire MSI data and the MS/MS spectra (beam diameter of 150 µm (H) x 
100 µm (W)). The MS/MS fragmentation was performed using an isolation window of 1 Da. 
MALDI-MSI data were acquired at a raster size of 100 × 100 μm in the mass range from m/z 100 
to 1000 in positive mode. Concerning the imaging experiments, the samples were optically 
scanned using a flatbed scanner to produce a digital image for future reference. This image was 
then imported into the MALDI imaging pattern creator software (High Definition Imaging (HDI) 
v1.2 software, Waters) to define the region to be imaged.  
A Bruker rapifleX MALDI Tissuetyper™ time-of-flight (TOF) instrument from Bruker Daltonics 
Inc. was used for high-speed imaging at a spatial 50 x 50 μm raster size. The acquisition rates 
were 50 pixels per second which was possible by using a 10-kHz laser and two rotating mirrors 
that allowed the laser beam to be moved over, and synchronized with, the rapidly moving sample. 
The data was acquired in the mass range m/z 100 to 1000 in positive ion mode.  
A Bruker SolariX Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer 
equipped with a 9.4T superconducting magnet was used to acquire high mass resolution spectra 
to confirm the molecular identity of TAA. The data were acquired in the mass range 100 to 2000 
m/z in positive ion mode (100 laser shots with 2000 Hz frequency).  
Histological Staining 
After performing the MALDI-MSI experiments, the matrix was removed by submersion in EtOH 
for 5 minutes. The sections were stained using hematoxylin for 10 min, Safranin O 0.1% 
dissolved in ultra-pure H2O for 4 min and Fast Green FCF 0.1 % dissolved in ultra-pure H2O for 
4 minutes. Digital images were acquired with the Mirax system (Carl Zeiss) after dehydrating 
steps. 
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Data analysis 
The profiles acquired on the target plates and the MS/MS spectra were analyzed using MassLynx 
v4.1 (Waters) and further processed using mMass v3.0 for presentation purposes 
(http://www.mmass.org/). The MALDI-MSI data acquired using the Waters MALDI HDMS 
SYNAPT G2-Si mass spectrometer were first converted using the HDI software v1.4 and 
visualized using BioMap software (Novartis, Basel, Switzerland). Regions of interest (ROIs) 
were manually created by BioMap for the calculation of the penetration of the drug in the tissues. 
For each experiment, the concentrations for dosed tissues were calculated using the standard 
curve obtained by the dilution series applied on blank tissues. Total ion count (TIC) was used to 
normalize the data until the incorporation of the labeled drug (TAA-d6) which was used to 
perform quantitation. The results of the experiments were averaged to obtain the final 
concentrations of incubated tissues. The standard deviation and the relative standard deviation 
were calculated for both 434.5 and 43.5 ng/µl TAA doses.34 FlexImaging v5.0 was used to 
process the mass spectral data acquired using the Bruker rapifleX. DataAnalysis 4.4 was used to 
analyze the FT data. The co-registration of the optical images, stained images and MSI data was 
done using markers on the ITO slides in the FlexImaging software.  
 
RESULTS AND DISCUSSION 
Detection of TAA. To gain insight about TAA in OA, we aimed to derivatize, localize, and 
quantify drug levels within dosed human cartilage by MALDI-MSI.  We first studied the 
behavior of the drug with different matrices by applying a TAA standard on a target plate. The 
detection of the standard was tested in both positive and negative ion modes with two different 
matrices, DHB and norharmane.  
The peak at m/z 435.23 [M+H]+ was observed with low intensity, as well as the sodium adduct 
m/z 457.22 [M+Na]+ and potassium adduct at m/z 473.19 [M+K]+ in positive ion mode for DHB 
(shown in Figure 1a). However, in negative ion mode, we did not obtain any signal using 
norharmane as a matrix (data not shown). Because of its hydrophobic properties, TAA required a 
chemical derivatization process in order to improve its ionization efficiency (Figure 1b). Two 
hydrazine-based reagents were chosen as candidates to derivatize TAA: the efficacy of the 
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reaction of 2,4-Dinitrophenylhydrazine (DNPH) and Girard’s reagent T (GirT) were compared 
under the same conditions (2 hours at ambient temperature, 100 ng/µl TAA; DHB). DNPH is the 
most commonly used reagent to improve the detection of carbonyl-containing compounds.29 Our 
experiments demonstrated higher ion intensities with GirT (3.93 107 a.u. for TAA at m/z 548.31 
[M]+) as well as the radical cation of TAA at m/z 434.24 ([M]+·) compared to DNPH (7.34 103 
a.u. at m/z 615.23 [M+H]+) (Figure 2, Supporting Information).  
 
Method development and optimization of the standard curve. With the successful detection 
of TAA using GirT, we proceeded to optimize the derivatization method. A TAA dilution series 
was prepared (0.1, 0.5, 1, 2, 10, 20, 30 and 50 ng/µl) and spotted on a target plate. A correlation 
coefficient (R2) of 0.9522 was obtained (triplicate’s average) with a relative intensity up to 4.62 
10-2 a.u. for the highest concentration (Figure 2a). When the reaction time was increased to 2.5 
hours, we obtained a R2 of 0.9823 (triplicate’s average) and a higher relative intensity for 50 
ng/µl up to 1.32 10-1 a.u. (Figure 2b). Other studies have shown that the reaction can be carried 
out at high temperatures for a shorter time.35 The mixed solution of TAA and GirT was incubated 
in an oven (40°C) for 1 hour which resulted in an R2 of 0.9112 (triplicate’s average) and a 
relative intensity of 5.71 10-1 a.u. (Figure 2c). We continued with the 40 °C incubation but 
increased the time to 2.5 hours; both the linearity of the conversion of TAA to hydrazones (R2 = 
0.998, triplicate’s average) and the relative intensity of TAA (8.91 10-1 a.u.) increased. From 
these data, we determined that incubation at 40°C for 2.5 hours yielded the most optimal 
conditions for TAA derivatization with GirT. Girard’s reagent T reacts with the carbonyl 
functionality of aldehydes and ketones to form a hydrazone derivative, which incorporates a 
permanent positive charge. Reactions using Girard’s reagents are typically conducted in organic 
solvents in the presence of an acidic catalyst and high temperatures.33,35,36 The experiments were 
initially performed at room temperature for 2 hours, this resulted in a instability and low yield of 
the derivative, as shown in the standard curve. As a result the temperature was increased to 40°C, 
this improved the yield of the derivative (10 fold) in a much shorter time. The yield of the 
derivative was further improved by increasing the reaction time to 2.5 hours at 40°C, no further 
increase in the yield of the derivative was observed with longer reaction times possibly due to the 
reaction being complete. The temperature was not further increased in order to maintain the 
integrity of the tissue sections. 
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On-tissue chemical derivatization. Next, we evaluated the efficiency of our derivatization 
protocol on tissue sections, using rat liver tissue. Previous studies have shown that when a 
dilution series is applied on tissue a linear standard curve can be obtained.37-39 The standard curve 
was spotted on a liver tissue section and the number of GirT and matrix layers were tested. While 
optimizing the efficiency of TAA derivatization on tissue, we observed spatial delocalization due 
to GirT not drying on the slide. This can be explained by the chemical properties of GirT: it is a 
quaternary amine salt and very hydroscopic. To solve this problem, we employed a soft/dry 
matrix application protocol, increasing the number of passes but decreasing the flow rate of the 
SunCollect (30 layers, 20 µl/min) to let the matrix dry between two passes (data not shown).  
In order to verify the derivatization of the drug on the cartilage tissue sections, 4 blank tissues, 3 
tissues incubated in the presence of 434.5 ng/µl TAA and 3 tissues with 43.5 ng/µl TAA were 
mounted on the same ITO slide per every donor. It is important to note that for this derivatization 
protocol, it is not possible to use tissues embedded in gelatin since the reaction of derivatization 
involves a step in the oven at 40°C. We showed with this experiment the potential to perform 
quantitation; the average signal for dosed tissues in 434.5 ng/µl was higher than incubated tissues 
in 43.5 ng/µl (data not shown). Using the rapifleX, we were able to detect a very low signal for 
non-derivatized TAA at m/z 435.2 [M+H]+. The TAA signal increased 78-fold between m/z 435.2 
[M+H]+ and m/z 548.3 [M]+ thanks to the derivatization protocol. The data and images for these 
experiments were normalized with TIC. MS/MS was performed on the peak at m/z 548.31 and 
confirmed the presence of TAA (Figure 3, Supporting Information). FT-ICR data were acquired 
to confirm the identity with an accuracy of 0.55 ppm (Figure 4, Supporting Information).  From 
these data, we conclude that derivatization using GirT increased the TAA signal in tissue 
sufficiently for quantitation.  
 
Optimization of the quantitation method using deuterated TAA on blank cartilage tissue 
sections. It has been shown that an internal standard is needed in order to quantify the levels of 
an endogenous compound.34 An internal standard also improves scan-to-scan reproducibility and 
improves the linearity of the calibration curve.40 Quantitation strategies using an internal standard 
have been successfully applied to quantify drug levels in tissue.25 Deuterated analogues routinely 
perform best as internal standards due to their similar chemical characteristics to the drug under 
study. Therefore, we employed a deuterated analogue of TAA to perform quantitative analyses 
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(Figure 3a, b). The behavior and ionization efficiency of both TAA and TAA-d6 were assessed. 
First, a dilution series was prepared for TAA and TAA-d6 (0.1, 0.5, 1, 2, 10, 20, 30 and 50 ng/µl). 
The standard curves for TAA and TAA-d6 were spotted on a target plate. The R
2 values were 
similar for TAA and TAA-d6 (0.9928 and 0.9909, respectively, in an average of three 
experiments), and the calibration curves were comparable (Figure 3c), indicating an identical 
ionization efficiency of the drug and its deuterated analogue. An 8-point standard curve was 
prepared on untreated cartilage tissue sections on the same ITO slide by manually applying an 
aliquot of 0.2 µl. We respectively obtained R2 values of 0.9903 and 0.9920 for TAA and TAA-d6 
(average of three experiments) with two fitted linear calibration curves. Moreover, the relative 
intensities were similar for each measured point of the curve (Figure 3d). We conclude that TAA 
and TAA-d6 have the same ionization efficiency, the same response factor and the same behavior 
in terms of ion-suppression effects, which makes TAA-d6 an ideal choice for quantitation of 
TAA. 
 
Quantitation of cartilage incubated with TAA. To quantify TAA in human cartilage after 
incubation with the drug, untreated cartilage sections, tissues from three human cartilage donors 
incubated in a solution at 434.5 ng/µl of TAA and three with 43.5 ng/µl of TAA were mounted 
on the same ITO slide. The internal standard was applied directly onto the tissue to use it as 
calibration curve.41 Nilsson et al. spotted the standard on top of the control tissue sections in 
order to confirm the identification of the drug crystals in kidney, by using this method.42 
Applying the internal standard on top of the tissue allows a uniform repartition of the standard all 
over the dosed sample. The ability to reliably and reproducibly deposit standards homogeneously 
on tissue is achieved with automatic deposition devices. Here, the internal standard (TAA-d6) was 
sprayed on top of the tissue using the SunCollect.41,43  An 8-point dilution series was spotted on 
the blank tissue sections in order to obtain a calibration curve. The experiment was repeated three 
times per donor using consecutive sections, resulting in standard curves with R12 = 0.9918, R22 = 
0.9993 and R32 = 0.9907. On cartilage, the TAA average intensity (m/z 548.31 [M]+) was 
normalized with the internal standard (Figure 4a). Using the calibration curves, we calculated the 
TAA concentration in the dosed tissues (Figure 4b): TAA in higher-dosed tissues was 22.19 ± 
2.11 ng/µl and in lower-dosed tissues was 3.66 ± 0.37 ng/µl (average ± SD from 3 experiments; 
Figure 4c). The concentrations were expressed in ng/µl following previous studies.43 The 
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experiment was repeated with cartilage from two other OA patients. The concentrations for the 
second patient were 10.34 ± 1.01 ng/µl for the highest-dosed tissues and 6.44 ± 0.57 ng/µl in 
lowest dosed tissues (average ± SD from 3 experiments) obtaining standard curves with R2 above 
0.99 (0.997, 0.9917 and 0.9976, respectively). The values for the third patient cartilage chips 
were 6.80 ± 0.05 ng/µl and 4.74 ± 0.23 ng/µl for the highest and lowest dosed tissues, 
respectively (Figure 4d). Moreover, TAA was also detectable in tissues incubated at 4.35 ng/µl 
(data not shown). The deuterated drug analogue reduced intra- tissue irregularities and allowed 
the drug quantitation. The precision of these experiments was 6.8mDa. 
 
Distribution of triamcinolone acetonide within the cartilage. The distribution of the drug was 
investigated at a spatial resolution of 50 µm. Different methods of normalization have been 
applied: Median, TIC and labeled normalization.  Staining of the tissue was performed after data 
acquisition to correlate the different images with the different cartilage zones (Figure 5a,b). Our 
findings show differences in the localization of TAA depending on the normalization method that 
has been used due to the difference in dynamic range between these methods.44 The non-
normalized image did not display a particular distribution of the drug within the tissue (Figure 
5c). Median normalization and TIC showed a non-homogeneous distribution of TAA within the 
tissue (Figure 5d, e) and a higher intensity in the superficial area of the cartilage. In comparison, 
normalization against the labeled analogue displayed a different distribution of the drug. With 
this normalization approach, the drug is concentrated in the middle zone of the incubated tissue 
(Figure 5f). The internal standard is homogeneously distributed on top of the tissue, however its 
ionization efficiency depends on the structure of the cartilage which leads to different absolute 
intensities observed between the different layers of the sections: the superficial layer of the 
cartilage contains a relatively high number of chondrocytes, being responsible of the protection 
and maintenance of deeper layers. This zone is in contact with synovial fluid and is able to resist 
the shear and tensile forces imposed by articulation. This layer is damaged and thinner in OA 
joints.45 Immediately underneath the superficial zone is the middle zone, representing about 60% 
of the total cartilage volume, and it contains proteoglycans and thicker collagen fibrils. In this 
layer, the collagen is organized obliquely, and the chondrocytes are spherical and at low density. 
The deep zone contains the largest diameter collagen fibrils, the highest proteoglycan content, 
and the lowest water concentration.46 The differences in cell number, proteoglycan and water 
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content could affect the ionization efficiency of TAA, as well as, the metabolism of the 
compound. Because of the role of each zone, it is extremely important to understand the diffusion 
of TAA and other drugs that are commonly used for OA treatment into the cartilage. We 
confirmed the importance of using an internal standard to perform quantitation but also to correct 
for tissue heterogeneity.44 In addition, the use of a labeled standard is crucial because TIC 
normalization is not able to take in account the structure of the tissue and by consequence the ion 
suppression effect. Normalization against a deuterated internal standard makes possible drug 
quantitation, which correlates with liquid chromatography-tandem mass spectrometry (LC-MS).47 
LC-MS is a very robust tool to perform identification and quantitation of drugs.48,49 The 
drawback of this technique is the loss of spatial information as an extraction of the tissue has to 
be performed before analysis. With MSI, the spatial distribution of the drug is preserved. The 
local ionization efficiency in imaging MS is tissue-type dependent. The use of the internal 
standard allows the correction of these tissue-dependent ionization differences as the deuterated 
analogue behaves the same as the drug in terms of extraction, co-crystallization with the matrix, 
and ionization efficiency.25 In addition, Pirman et al. showed that the use of an internal standard 
improves the quality of the MS images40 and moreover, the deuterated analogue is demonstrated 
to improve the quantitation.50,51 In a recent study, Chumblay et al. compared different ways of 
applying the internal standard, showing that spraying the internal standard on tissue was the most 
accurate technique compared with HPLC-MS, obtaining similar concentrations with both 
aproaches.52 Therefore LC-MS and MALDI-MSI are two complementary tools in drug discovery 
to look at the quantitation and the distribution/penetration of the drug within biological tissues. 
Other strategies such as liquid extraction surface analysis (LESA) can provide an intermediate 
solution since it provides information regarding the spatial distribution; it can be coupled to LC, 
and therefore improving the sensitivity, limiting tissue suppression effect and eliminating matrix 
interferences. However, typically the spatial resolution is limited to hundreds of micrometers. 
53,54To our knowledge, there are no previous studies that demonstrate if TAA is actually 
penetrating the cartilage. Only measurements on synovial fluid or plasma are used as read 
outs.55,56  
The low TAA amounts we measured in cartilage explants incubated in two different 
concentrations, can be due to the fact that the drug may be metabolized at ~48 h, so we were only 
able to measure the remaining intact portion. Additionally, we observed a patient dependent 
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difference in the speed of of TAA metabolisms. This could be due to differences in OA grade, 
cellularity or the composition of the extracellular matrix. Whether TAA concentrations will be 
higher with shorter incubation times (<48 h) in other areas of the cartilage remains to be 
determined. Whereas our study is based on incubated tissues, this method is applicable to treated 
tissue to evaluate drug distribution and to correlate the effects of the drug with its quantified 
distribution.  
In summary, the detection and quantification of the anti-inflammatory TAA compound at 50 µm 
of lateral resolution for incubated tissues opens the door to understand the behavior of these 
pharmaceuticals in the treatment of OA and other inflammatory pathologies. Our work provides 
an important step for further studies examining the distribution of TAA in OA cartilage.  
 
CONCLUSIONS 
These studies report that drug derivatization combined with MALDI-MSI is an innovative way to 
study the penetrance of triamcinolone acetonide within treated human cartilage. To the best of 
our knowledge, this is the first paper to report the detection and quantification of a drug in 
cartilage tissues by MSI. Future experiments must study the distribution of the drug at shorter and 
longer times of incubation as well as its distribution in an in vivo model by using the method 
presented in this paper. We demonstrated and confirmed the applicability of an isotopically 
labelled internal standard to perform an accurate and quantitative study of drug distribution 
within biological tissues.  
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FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Derivatization of triamcinolone acetonide (TAA) with Girard reagent T (GirT) on 
a target plate. (a) Non-derivatized TAA was detectable at m/z 435.23 [M+H]+ as well as cation 
species at m/z 457.22 [M+Na]+ and m/z 473.19 [M+K]+. Using the derivatization protocol, non-
derivatized-TAA was detectable at m/z 434.24 [M]+· but the highest signal was for the 
derivatized-TAA at m/z 548.33 [M]+. (b) TAA was mixed with GirT obtaining the derivatized 
form of TAA.  
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Figure 2. Optimization of the derivatization reaction using a 8 point calibration curve. The 
optimization of the chemical reaction has been performed by mixing TAA with GirT for (a) 2 
hours and (b) 2.5 hours at ambient temperature. (c) The derivatization process shows a higher 
intensity (5.71 10-1) placing the solution in an oven for 1 hour. Optimal and reproducible 
conditions were (d) 2.5 hours at 40°C. Each experiment has been repeated 3 times and the 
averaged R2 is represented in this figure.   
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Figure 3. Behavior of the triamcinolone acetonide and deuterated triamcinolone acetonide 
on a target plate and on tissue. Chemical structures of (a) TAA and (b) deuterated analogue 
TAA-d6, hydrogen atoms have been replaced with deuterium atoms inducing a mass shift of +6 
m/z on the mass spectrum. (c) Standard curves of TAA (m/z 548.3 [M]+ ) and TAA-d6 (m/z 554.3 
[M]+) spotted on a target plate. (d) Standard curves of TAA and TAA-d6 spotted on blank 
cartilage tissue sections. The standard curves have been spotted on the same target plate and on 
the same ITO slide in triplicate.   
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Figure 4. Molecular imaging and quantitation by MALDI-MSI of triamcinolone acetonide. 
(a) Three human donors were analyzed with the Synapt G2-Si. The MALDI-MSI images were 
normalized with TAA-d6. Four blank tissue sections with a spotted 8-point standard curve, six 
dosed tissues (three incubated in 434.5 ng/µl and three with 43.5 ng/µl TAA) were placed on an 
ITO slide. (b) For each experiment, a standard curve was obtained and the average intensities of 
the tissues were extrapolated to obtain the concentrations. (c) Quantification of TAA in three 
human OA patient explant cartilages treated with TAA. (d) Summary table of triamcinolone 
acetonide quantitation in different cartilage tissue sections for three different donors.  
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Figure 5. MALDI-MSI distribution of triamcinolone acetonide (TAA) on incubated 
osteoarthritis cartilage tissue sections using different normalization methods. (a) Digital 
photographic images of cartilage tissue sections with matrix applied on the tissue before MALDI-
MSI measurement. (b) The cartilage section was stained to show the different structures of the 
tissue. The tissue was incubated in a TAA solution (43.5 ng/µl), and the drug distribution can be 
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observed using non-normalization (c), median normalization (d), TIC normalization (e), or 
normalization against the labeled analogue of the drug (f). Only the labeled normalization 
showed a homogeneous distribution, reducing ion-suppression effects due to spatial heterogeneity 
of the cartilage.  
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